Multimodal Validation and Disease Stage Dependency of ATTR Cardiomyopathy Red Flags in Patients With LV Thickening
INTRODUCTION: Timely diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) is critical to improving outcomes and remains challenging. Guidelines recommend assessing for red flags (RFs) to facilitate ATTR-CM detection, but their diagnostic validation remains incomplete. This study aimed to multidimensionally validate these RFs in patients with left ventricular thickening (LVT). METHODS: Prospective registry study including all patients with LVT and standardized workup at tertiary amyloidosis center. For validated RFs, "high-risk" (specificity for ATTR-CM>90%) and "low-risk" (false-negative rate<5%) findings were predefined. RESULTS: 425 patients (321 ATTR-CM,104 control group) were included. Heart failure (97%) and polyneuropathies (78%) were among most sensitive clinical findings, while bilateral carpal tunnel syndrome (bCTS) was more specific (80%) but less sensitive (45%). Diverse ECG changes were common, yet mostly unspecific. Marked elevations of NT-proBNP and troponin were most discriminative among non-imaging RFs (Youden's index[YI]:59%). Apical sparing (Apical-to-Basal-strain-ratio≥2.0) was the most effective, stage-independent echocardiographic parameter (YI62%), followed by biatrial enlargement, advanced diastolic dysfunction, and LVGLS impairment (YI48-55%). Normal ECG without conduction disorders history and normal levels of both NT-proBNP and hs-troponin-T constituted "low-risk" findings. Heart failure with concomitant bCTS, peripheral low voltage, right ventricular dysfunction, 5-5-5 sign, restrictive filling pattern and apical sparing with LVGLS impairment represented "high-risk" RFs. Contrary to most non-imaging RFs, most echocardiographic RFs showed association with advancing disease stage (p<0.05). All aforementioned RFs were associated with ATTR-CM independently of age, sex, and LVT-severity (p<0.05). CONCLUSIONS: ATTR-CM is frequently associated with validated RFs that differ in their diagnostic characteristics, which should be considered when evaluating for ATTR-CM.
Authors
- Nicolas W. Wieder (ORCID: https://orcid.org/0000-0001-5683-2891)
- Bettina Heidecker (ORCID: https://orcid.org/0000-0002-3811-7920)
- Elena Romero Dorta (ORCID: https://orcid.org/0000-0002-7641-4467)
- Christoph Wetz (ORCID: https://orcid.org/0000-0002-7392-1375)
- Gerhard Hindricks (ORCID: https://orcid.org/0000-0002-0132-0773)
- Sebastian Spethmann (ORCID: https://orcid.org/0000-0003-0987-8007)
- Isabel Mattig (ORCID: https://orcid.org/0000-0001-8455-3750)
- Jan Gröschel (ORCID: https://orcid.org/0000-0002-7268-9041)
- Stefanie Maria Werhahn (ORCID: https://orcid.org/0000-0002-0805-3129)
- Gina Barzen (ORCID: https://orcid.org/0000-0002-1329-2159)
- Paul J Wetzel (ORCID: https://orcid.org/0009-0001-9393-5512)
- Jeanette Schulz‐Menger (ORCID: https://orcid.org/0000-0003-3100-1092)
- Katrin Hahn (ORCID: https://orcid.org/0000-0002-6013-0072)
- Helena F Pernice (ORCID: https://orcid.org/0009-0001-8711-5526)
- Friedrich Koehler (ORCID: https://orcid.org/0000-0003-0441-4123)
- Jasmin Zernikow (ORCID: https://orcid.org/0009-0000-0718-0823)
- Vera von Landenberg-Roberg
- Jakub Piwowarski (ORCID: https://orcid.org/0009-0000-0941-9084)
Institutions
- Humboldt-Universität zu Berlin (DE)
- Deutsches Herzzentrum der Charité (DE)
- Amyloidosis Foundation (US)
- German Centre for Cardiovascular Research (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1093/eschf/xvag285
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00